Lead Product(s): Voxelotor
Therapeutic Area: Genetic Disease Product Name: Oxbryta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Global Blood Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2020
Oxbryta is a once-daily, oral therapy that directly inhibits hemoglobin polymerization for the treatment of SCD. Biopharma-MEA will distribute Oxbryta® (voxelotor) tablets in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.